Gamma radiolytic stability of the novel modified diglycolamide 2,2'-oxybis(N,N-didecylpropanamide) (mTDDGA) for grouped actinide extraction.

Reprocessing of spent nuclear fuel aims at improving resource efficiency and reducing its radiotoxicity and heat production in the long term. The necessary separation of certain metal ions from the spent fuel solutions can be achieved using different solvent extraction processes. For the scenario of the EURO-GANEX process, the use of the new, modified diglycolamide 2,2'-oxybis(N,N-didecylpropanamide) (mTDDGA) was recently proposed to simplify the current solvent composition and reduce extraction of fission products. Before further developing the process based on this new ligand, its stability under ionizing radiation conditions needs to be studied. For this reason, gamma irradiation experiments were conducted followed by analyses with high performance liquid chromatography coupled to a mass spectrometer (HPLC-MS). The determined degradation rate of mTDDGA was found to be lower than that of the reference molecule N,N,N',N'-tetra-n-octyl-diglycolamide (TODGA). Many identified degradation compounds of both molecules are analogues showing the same bond breaking, although also unreported de-methylation, double/triple de-alkylation and n-dodecane addition products were observed.

In Vivo Pharmacokinetics, Biodistribution and Toxicity of Antibody-Conjugated Gold Nanoparticles in Healthy Mice.

Cetuximab-conjugated gold nanoparticles are known to target cancer cells, but display toxicity towards normal kidney, liver and endothelial cells in vitro. In this study, we investigated their pharmacokinetics, biodistribution and toxicity after intravenous administration in healthy mice. Our data showed that these nanoparticles were rapidly cleared from the blood and accumulated mainly in the liver and spleen with long-term retention. Acute liver injury, inflammatory activity and vascular damage were transient and negligible, as confirmed by the liver functionality tests and serum marker analysis. There was no sign of altered liver, kidney, lung and spleen morphology up to 4 weeks post-injection. After 6 months, kidney casts and splenic apoptosis appeared to be more prevalent than in the controls. Furthermore, occasional immune cell infiltration was observed in the lungs. Therefore, we recommend additional in vivo studies, in order to investigate the long-term toxicity and elimination of gold nanoparticles after multiple dosing in their preclinical validation as new targeted anti-cancer therapies.